- Home
- LSBK vs JSPR Comparison
LSBK vs JSPR Comparison
Compare LSBK & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | JSPR |
|---|---|---|
| Founded | 1891 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 26.3M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LSBK | JSPR |
|---|---|---|
| Price | $18.95 | $0.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 23.7K | ★ 322.1K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 49.23 | 19.22 |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $0.32 |
| 52 Week High | $19.09 | $2.69 |
Technical Indicators
Market Signals| Indicator | LSBK | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 46.74 |
| Support Level | $16.84 | $0.64 |
| Resistance Level | $19.09 | $1.01 |
| Average True Range (ATR) | 0.55 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 42.47 | 50.00 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.